StockData

Myriad Genetics vs OPKO Health

MYGN and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MYGN and OPK compare

OPKO Health is the larger company, worth 2.3 times as much as Myriad Genetics ($1.2B against $530M).

Myriad Genetics grew revenue faster over the last twelve months (−3.2% versus −11.5% for OPKO Health).

OPKO Health keeps more of each dollar of sales as profit, with a net margin of −12.4% compared with −14.0% at Myriad Genetics.

OPKO Health scores higher on the StockData Score (9 against 8 for Myriad Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMYGNOPK
Size and price
Market cap$530M$1.2B
Share price$5.54$1.62
Change, 1 year−17.4%26.6%
Change, 5 years−79.2%−60.8%
Beta (5Y)−0.090.36
Employees2,7002,275
StockData Score
Total score89 (better)
Valuation score3 (better)1
Growth score01 (better)
Performance score33
Health score24 (better)
Dividend score00
Valuation
P/S0.7× (better)2.1×
P/B1.7×1.0× (better)
EV/EBITDA–22.0×
FCF yield–−11.1%
Fair value$18.25$1.55
Margin of safety69.6% (better)−4.7%
Growth
Revenue growth (TTM)−3.2% (better)−11.5%
Revenue growth, 5Y average−0.63% (better)−15.8%
Profitability
Gross margin68.8% (better)40.8%
Operating margin−12.2%−8.2% (better)
Net margin−14.0%−12.4% (better)
FCF margin–−22.8%
Return on equity−32.5%−5.9% (better)
Return on invested capital−22.8%−4.0% (better)
Financial health
Debt / equity0.400.00 (better)
Net debt / EBITDA–−7.19
Interest coverage−6.0×–
Current ratio2.213.35 (better)
Altman Z-score−0.63−0.21 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–3.9%
Shareholder yield0.00%3.9% (better)
Ownership
Held by institutions94.1%27.2%
Held by insiders7.2%43.6%
Insider net buying, 12 months$655K (better)−$13.2K
Short interest, % of float9.5%7.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.